Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1258

1.

Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.

Kroenke K, Messina N 3rd, Benattia I, Graepel J, Musgnung J.

J Clin Psychiatry. 2006 Jan;67(1):72-80.

PMID:
16426091
2.
3.

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.

Davidson JR, DuPont RL, Hedges D, Haskins JT.

J Clin Psychiatry. 1999 Aug;60(8):528-35.

PMID:
10485635
4.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
5.

A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.

Liebowitz MR, Mangano RM, Bradwejn J, Asnis G; SAD Study Group.

J Clin Psychiatry. 2005 Feb;66(2):238-47.

PMID:
15705011
6.

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.

Liebowitz MR, Gelenberg AJ, Munjack D.

Arch Gen Psychiatry. 2005 Feb;62(2):190-8.

PMID:
15699296
7.
8.

Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.

Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Pedersen R, Musgnung J.

Arch Gen Psychiatry. 2006 Oct;63(10):1158-65.

PMID:
17015818
9.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
10.

Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.

Feighner JP, Entsuah AR, McPherson MK.

J Affect Disord. 1998 Jan;47(1-3):55-62.

PMID:
9476744
12.
14.

Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder.

Lydiard RB, Pitrosky B, Hackett D, White C.

J Clin Psychiatry. 2004 Jun;65(6):838-44.

PMID:
15291662
15.

Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity.

Sauer H, Huppertz-Helmhold S, Dierkes W.

Pharmacopsychiatry. 2003 Sep;36(5):169-75.

PMID:
14571350
17.

Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.

Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D.

Depress Anxiety. 2002;16(1):4-13.

PMID:
12203668
18.
20.

A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.

Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB.

J Clin Psychiatry. 2006 Feb;67(2):288-96.

PMID:
16566626

Supplemental Content

Support Center